{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:50Z","timestamp":1790911250928,"version":"4.1.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["P30 CA046592"],"award-info":[{"award-number":["P30 CA046592"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["R37CA233476"],"award-info":[{"award-number":["R37CA233476"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["R01CA236722"],"award-info":[{"award-number":["R01CA236722"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:p>The reciprocal relationship between malignant T cells and lymphoma-associated macrophages (LAM) within the tumor microenvironment (TME) is unique, as LAMs are well poised to provide ligands for antigen, costimulatory, and cytokine receptors that promote T-cell lymphoma growth. Conversely, malignant T cells promote the functional polarization and homeostatic survival of LAM. Therefore, we sought to determine the extent to which LAMs are a therapeutic vulnerability in these lymphomas, and to identify effective therapeutic strategies for their depletion. We utilized complementary genetically engineered mouse models and primary peripheral T-cell lymphoma (PTCL) specimens to quantify LAM expansion and proliferation. A high-throughput screen was performed to identify targeted agents that effectively deplete LAM within the context of PTCL. We observed that LAMs are dominant constituents of the TME in PTCL. Furthermore, their dominance was explained, at least in part, by their proliferation and expansion in response to PTCL-derived cytokines. Importantly, LAMs are a true dependency in these lymphomas, as their depletion significantly impaired PTCL progression. These findings were extrapolated to a large cohort of human PTCL specimens where LAM proliferation was observed. A high-throughput screen demonstrated that PTCL-derived cytokines led to relative resistance to CSF1R selective inhibitors, and culminated in the identification of dual CSF1R\/JAK inhibition as a novel therapeutic strategy to deplete LAM in these aggressive lymphomas. Malignant T cells promote the expansion and proliferation of LAM, which are a bone fide dependency in these lymphomas, and are effectively depleted with a dual CSF1R\/JAK inhibitor.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>LAMs are a therapeutic vulnerability, as their depletion impairs T-cell lymphoma disease progression. Pacritinib, a dual CSF1R\/JAK inhibitor, effectively impaired LAM viability and expansion, prolonged survival in preclinical T-cell lymphoma models, and is currently being investigated as a novel therapeutic approach in these lymphomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0336","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T10:09:13Z","timestamp":1671012553000},"page":"1727-1737","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting Lymphoma-associated Macrophage Expansion via CSF1R\/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-1522","authenticated-orcid":true,"given":"Xin","family":"Gao","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8670-8752","authenticated-orcid":true,"given":"Nermin","family":"Kady","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-2117","authenticated-orcid":true,"given":"Chenguang","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-0074","authenticated-orcid":true,"given":"Suhaib","family":"Abdelrahman","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-2900","authenticated-orcid":true,"given":"Peter","family":"Gann","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Illinois Chicago, Chicago, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1893-865X","authenticated-orcid":true,"given":"Maria","family":"Sverdlov","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Illinois Chicago, Chicago, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0340-2788","authenticated-orcid":true,"given":"Ashley","family":"Wolfe","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-5912","authenticated-orcid":true,"given":"Noah","family":"Brown","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-2410","authenticated-orcid":true,"given":"John","family":"Reneau","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-9641","authenticated-orcid":true,"given":"Aaron M.","family":"Robida","sequence":"additional","affiliation":[{"name":"5Life Sciences Institute, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-5066","authenticated-orcid":true,"given":"Carlos","family":"Murga-Zamalloa","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Illinois Chicago, Chicago, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-0760","authenticated-orcid":true,"given":"Ryan A.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.24992","article-title":"Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)","volume":"93","author":"Zhang","year":"2018","journal-title":"Am J Hematol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10428194.2010.529204","article-title":"Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified","volume":"52","author":"Zhang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"65284","DOI":"10.18632\/oncotarget.11673","article-title":"GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-16-1996","article-title":"T-cell receptor signaling activates an ITK\/NF-kappaB\/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"110695","DOI":"10.1016\/j.celrep.2022.110695","article-title":"Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma","volume":"39","author":"Cortes","year":"2022","journal-title":"Cell Rep"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1126\/science.1204351","article-title":"Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation","volume":"332","author":"Jenkins","year":"2011","journal-title":"Science"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1084\/jem.20121999","article-title":"IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1","volume":"210","author":"Jenkins","year":"2013","journal-title":"J Exp Med"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1189\/jlb.0903442","article-title":"Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene","volume":"75","author":"Burnett","year":"2004","journal-title":"J Leukoc Biol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"35782","DOI":"10.18632\/oncotarget.6042","article-title":"Bone marrow macrophages support prostate cancer growth in bone","volume":"6","author":"Soki","year":"2015","journal-title":"Oncotarget"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3892\/or.2013.2508","article-title":"Investigating the role of macrophages in tumor formation using a MaFIA mouse model","volume":"30","author":"Clifford","year":"2013","journal-title":"Oncol Rep"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1099472","article-title":"Defining a link with asthma in mice congenitally deficient in eosinophils","volume":"305","author":"Lee","year":"2004","journal-title":"Science"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1172\/JCI37210","article-title":"TCR-dependent transformation of mature memory phenotype T cells in mice","volume":"121","author":"Wang","year":"2011","journal-title":"J Clin Invest"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41467-020-15821-9","article-title":"Consistent RNA sequencing contamination in GTEx and other data sets","volume":"11","author":"Nieuwenhuis","year":"2020","journal-title":"Nat Commun"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"110058","DOI":"10.1016\/j.celrep.2021.110058","article-title":"Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues","volume":"37","author":"Millard","year":"2021","journal-title":"Cell Rep"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"637143","DOI":"10.3389\/fnmol.2021.637143","article-title":"Estimating and correcting for off-target cellular contamination in brain cell type specific RNA-seq data","volume":"14","author":"Sicherman","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2013.125","article-title":"Loss of p53 and altered miR15-a\/16-1 MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-\/-) mouse model and primary human leukemia cells","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/ni.2638","article-title":"Origin of monocytes and macrophages in a committed progenitor","volume":"14","author":"Hettinger","year":"2013","journal-title":"Nat Immunol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-15-3099","article-title":"Colony-stimulating factor-1 receptor is required for nurse-like cell survival in chronic lymphocytic leukemia","volume":"22","author":"Polk","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-022-00745-y","article-title":"GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms","volume":"12","author":"Geng","year":"2022","journal-title":"Blood Cancer J"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2020007145","article-title":"Tumor-associated myeloid cells provide critical support for T-ALL","volume":"136","author":"Lyu","year":"2020","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRP\u03b1 requires Fc-Fc\u03b3R interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"e30947","DOI":"10.7554\/eLife.30947","article-title":"Myeloid cell recruitment versus local proliferation differentiates susceptibility from resistance to filarial infection","volume":"7","author":"Campbell","year":"2018","journal-title":"Elife"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/eji.201646442","article-title":"IL-33 delivery induces serous cavity macrophage proliferation independent of interleukin-4 receptor alpha","volume":"46","author":"Jackson-Jones","year":"2016","journal-title":"Eur J Immunol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/1535-7163.MCT-16-0157","article-title":"Macrophage susceptibility to emactuzumab (RG7155) treatment","volume":"15","author":"Pradel","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","article-title":"Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-cell lymphoma viability","volume":"26","author":"Murga-Zamalloa","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"2023032314110457500_","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0336\/3231310\/crc-22-0336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1727\/3285166\/crc-22-0336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1727\/3285166\/crc-22-0336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T18:26:57Z","timestamp":1701541617000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/12\/1727\/712423\/Targeting-Lymphoma-associated-Macrophage-Expansion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,30]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0336","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551058.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545930.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545957.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551058","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545963.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545960.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545942","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545936","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545939.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545948","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545936.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545954.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545951.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545933.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545951","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545948.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545945.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545945","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545942.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}